Fintel reports that on January 10, 2025, Truist Securities initiated coverage of BioNTech SE - Depositary Receipt () (NasdaqGS:BNTX) with a Buy recommendation.
Analyst Price Forecast Suggests 14.22% Upside
As of December 23, 2024, the average one-year price target for BioNTech SE - Depositary Receipt () is $139.52/share. The forecasts range from a low of $100.23 to a high of $180.02. The average price target represents an increase of 14.22% from its latest reported closing price of $122.15 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for BioNTech SE - Depositary Receipt () is 5,355MM, an increase of 76.15%. The projected annual non-GAAP EPS is 5.12.
What is the Fund Sentiment?
There are 448 funds or institutions reporting positions in BioNTech SE - Depositary Receipt (). This is an increase of 52 owner(s) or 13.13% in the last quarter. Average portfolio weight of all funds dedicated to BNTX is 0.37%, an increase of 42.59%. Total shares owned by institutions increased in the last three months by 9.83% to 52,591K shares. 
The put/call ratio of BNTX is 0.73, indicating a bullish outlook.
What are Other Shareholders Doing?
Baillie Gifford holds 8,308K shares. In its prior filing, the firm reported owning 8,276K shares , representing an increase of 0.38%. The firm increased its portfolio allocation in BNTX by 42.52% over the last quarter.
Primecap Management holds 4,517K shares. In its prior filing, the firm reported owning 4,790K shares , representing a decrease of 6.04%. The firm increased its portfolio allocation in BNTX by 41.54% over the last quarter.
Flossbach Von Storch holds 4,360K shares. In its prior filing, the firm reported owning 4,379K shares , representing a decrease of 0.46%. The firm increased its portfolio allocation in BNTX by 37.66% over the last quarter.
VHCOX - Vanguard Capital Opportunity Fund Investor Shares holds 2,271K shares. In its prior filing, the firm reported owning 2,372K shares , representing a decrease of 4.47%. The firm increased its portfolio allocation in BNTX by 40.42% over the last quarter.
Temasek Holdings holds 1,807K shares. No change in the last quarter.
BioNTech SE Background Information
(This description is provided by the company.)
BioNTech SE is a German biotechnology company based in Mainz that develops and manufactures active immunotherapies for patient-specific approaches to the treatment of diseases.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
